PBE
Invesco Biotechnology & Genome ETF
ETF
$95.07−0.03 (−0.03%)Close Oct 2, 2026
Adjusted price
+34.15% total return, past year
Key statistics
- Expense ratio
- 0.58%
- 52-week range
- $70.36$98.73
- From all-time high
- −3.71%
- Max drawdown
- −45.69%
- Volatility
- 25.20%
- Sharpe ratio
- 0.48
- Beta (5Y monthly)
- 0.70
- Median dollar volume
- $1.08M
- First close
- Jun 23, 2005
Returns
Total
- 1M
- −3.6%
- YTD
- +17.0%
- 1Y
- +34.2%
Per year
- 3Y
- +20.0%
- 5Y
- +5.4%
- 10Y
- +8.9%
- 20Y
- +9.4%
- Since 2005
- +9.4%
Fund facts
As of Jul 31, 2026- Net assets
- $282M
- Holdings
- 33
- Top 10 holdings
- 56.8%
- Stocks
- 100.0%
- Cash
- 17.9%
Sectors
- Health Care
- 100.0%
Top holdings
| Holding | Weight (%) |
|---|---|
| Invesco Private Prime Fund | 12.9 |
| REGNRegeneron Pharmaceuticals, Inc. | 5.5 |
| AMGNAmgen Inc. | 5.2 |
| CDNACareDx, Inc. | 5.0 |
| VRTXVertex Pharmaceuticals Incorporated | 5.0 |
| Invesco Private Government Fund | 5.0 |
| RPRXRoyalty Pharma plc | 4.9 |
| BIIBBiogen Inc. | 4.8 |
| GILDGilead Sciences, Inc. | 4.4 |
| UTHRUnited Therapeutics Corporation | 4.1 |
Annual returns
2005 from Jun 23 · 2026 through Oct 2